

STRATEGIC PARTNERSHIP & FINANCIAL ADVISOR APPOINTMENT

Invitrocue Ltd (IVQ)

14th July 2025 : Invitrocue Pte. Ltd. (“IVQ”), a precision oncology diagnostic company based in Singapore, and GeneCast Co. Ltd. (“GC”), a South Korean cancer diagnostics firm, are pleased to announce the signing of a strategic agreement that marks the beginning of a merger aimed at enhancing both companies’ global capabilities and long-term growth.

To support this strategic transaction and its broader corporate development goals, Invitrocue has appointed **Alchemy Capital Solutions (ACS)** as its exclusive lead advisor. Under the agreement signed, Alchemy will work closely with Invitrocue’s management team to provide high-level strategic planning, advise on capital structure and business synergies, and coordinate investor communications, financial modelling, and due diligence efforts. Alchemy’s role also includes supporting Invitrocue in identifying suitable financial and strategic partners, overseeing third-party advisor appointments, and guiding the execution of the merger integration process.

The partnership between Invitrocue and GeneCast reflects a shared commitment to combining complementary technologies, streamlining operations, and expanding access to advanced diagnostics across global markets. Invitrocue’s flagship service, **Onco-PDO**, uses patient-derived organoids—miniature 3D replicas of a patient’s own tumour grown in the lab—to test and predict how different cancer treatments will perform before they are given to the patient. This enables oncologists to personalize therapy decisions and avoid ineffective treatments. On the other hand, **GeneCast’s ADPS PCR** (Allele-Discriminating Priming System Polymerase Chain Reaction) is an ultra-sensitive genetic testing technology used for **monitoring cancer recurrence and treatment response** through simple blood tests. ADPS PCR can detect minute traces of circulating tumour DNA, making it possible to catch cancer relapse early or confirm whether a treatment is working.

Together, these platforms provide a **comprehensive “test- and-monitor-” solution**: Invitrocue’s Onco-PDO helps choose the most effective therapy at the start, while GeneCast’s ADPS PCR tracks the treatment’s real-time effectiveness and signals relapse early. This **synergy between functional and molecular precision diagnostics** creates a powerful closed-loop system for truly personalized cancer care. It also unlocks



significant **clinical and commercial value** in global markets, where oncologists and healthcare systems are increasingly shifting toward precision medicine.

Dr. Steven Fang, CEO of Invitrocue, commented, “This agreement marks a bold new chapter for both companies. Together, we aim to bring cutting-edge cancer diagnostics to more patients worldwide and build a stronger, more integrated business. The support of ACS will be instrumental in guiding us through this complex strategic journey.”

Dr. Byung Chul Lee, CEO of GeneCast, added, “This collaboration is more than a financial transaction—it is a strategic alignment of two companies with shared vision and values. By working alongside Invitrocue and with the advisory support of Alchemy Capital Solutions, we are positioning ourselves to lead innovation in molecular diagnostics and deliver long-term value to patients, partners, and shareholders.

With complementary technologies, global ambitions, and aligned missions, Invitrocue and GeneCast are well-positioned to become a **World-in-Class and First-in-Class precision oncology partner**, delivering better clinical outcomes for cancer patients while creating long-term value for healthcare providers and shareholders alike.

For further information and inquiry, please contact:

INVITROCUE

Dr. Steven Fang

CEO, Invitrocue Ltd

M: +65 6460 0497

E: steven.fang@invitrocue.com

Website : <https://invitrocue.com>

ALCHEMY CAPITAL SOLUTIONS

Mr. Matthia Tomba

mattia@thepio.co

<https://alchemycapitalsolutions.com>